RNF43 mutation
|
CRC
|
RNF43 mutation
|
CRC
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
RNF43 mutation
|
CRC
|
RNF43 mutation
|
CRC
|
encorafenib Sensitive: C3 – Early Trials
|
encorafenib Sensitive: C3 – Early Trials
|
RNF43 mutation
|
CRC
|
RNF43 mutation
|
CRC
|
cetuximab + alpelisib + encorafenib Sensitive: C3 – Early Trials
|
cetuximab + alpelisib + encorafenib Sensitive: C3 – Early Trials
|
RNF43 mutation
|
Bladder Cancer
|
RNF43 mutation
|
Bladder Cancer
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
RNF43 mutation
|
Pancreatic Ductal Adenocarcinoma
|
RNF43 mutation
|
Pancreatic Ductal Adenocarcinoma
|
avelumab + binimetinib Sensitive: C3 – Early Trials
|
avelumab + binimetinib Sensitive: C3 – Early Trials
|
RNF43 mutation
|
CRC
|
RNF43 mutation
|
CRC
|
PORCN inhibitor Sensitive: D – Preclinical
|
PORCN inhibitor Sensitive: D – Preclinical
|